STOCK TITAN

Capstone Holding (OTC: CAPS) amends CEO 356,250-share stock award details

(Neutral)
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Lipman Matthew E. reported acquisition or exercise transactions in this Form 4 filing.

Capstone Holding Corp. amended a prior insider report to clarify that Chief Executive Officer Matthew E. Lipman received a grant of 356,250 shares of common stock as restricted stock awards on March 30, 2026, vesting in full on March 30, 2029, for no consideration.

After this grant, he directly holds 2,920,340 shares of common stock. This figure excludes an additional 121,774 shares he controls through BP Peptides, LLC.

Positive

  • None.

Negative

  • None.
Insider Lipman Matthew E.
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Stock F1, F2, F3 356,250 -- --
Holdings After Transaction: Common Stock — 2,920,340 shares (Direct)
Footnotes (3)
  1. F1. This Form 4/A is being filed solely to correct the nature of the shares reported as granted on April 1, 2026. This amendment reflects that the shares granted were shares of common stock, rather than restricted stock units.
  2. F2. Including 356,250 shares of common stock granted to the Reporting Person on March 30, 2026 as restricted stock awards, for no consideration. The restricted stock awards vest in full on March 30, 2029, which is the third anniversary of the March 30, 2026 grant date, subject to the Reporting Person's continued service through such vesting date.
  3. F3. Excludes 121,774 shares controlled by the Reporting Person, through his control of BP Peptides, LLC.
Restricted stock awards granted 356,250 shares of common stock Shares granted to CEO Matthew E. Lipman on March 30, 2026 as restricted stock awards
Vesting date March 30, 2029 Restricted stock awards vest in full on the third anniversary of the grant date
Direct holdings after grant 2,920,340 shares Total shares of Capstone common stock directly owned by the CEO following the award
Indirectly controlled shares excluded 121,774 shares Shares controlled through BP Peptides, LLC that are excluded from the direct holdings total
restricted stock awards financial
"Including 356,250 shares of common stock granted to the Reporting Person on March 30, 2026 as restricted stock awards"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
restricted stock units financial
"reflects that the shares granted were shares of common stock, rather than restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 4/A financial
"This Form 4/A is being filed solely to correct the nature of the shares reported"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
continued service financial
"vest in full on March 30, 2029, which is the third anniversary ... subject to the Reporting Person's continued service"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What change does Capstone Holding Corp. (CAPS) report in this Form 4/A?

The amendment clarifies that a previously reported equity grant to CEO Matthew E. Lipman consisted of common stock, not restricted stock units. It restates the nature of the March 30, 2026 award without changing the reported share count or vesting schedule.

How many Capstone Holding Corp. (CAPS) shares were granted to the CEO?

CEO Matthew E. Lipman was granted 356,250 shares of common stock as restricted stock awards on March 30, 2026. The award was made for no consideration and is subject to vesting conditions tied to his continued service with the company.

When do the CAPS CEO’s restricted stock awards vest?

The 356,250 restricted stock awards granted on March 30, 2026 vest in full on March 30, 2029. Vesting is conditioned on Matthew E. Lipman’s continued service with Capstone Holding Corp. through that vesting date, as described in the grant terms.

How many Capstone Holding Corp. (CAPS) shares does the CEO own after this grant?

Following the grant, Matthew E. Lipman directly owns 2,920,340 shares of Capstone common stock. This direct holding figure separately excludes 121,774 shares that he controls through BP Peptides, LLC, which are noted but not included in the direct total.

Were the CAPS CEO’s newly reported shares purchased for cash?

No, the 356,250 shares were granted as restricted stock awards for no consideration. They represent an equity compensation grant rather than an open-market purchase, and they are subject to vesting based on continued service through March 30, 2029.

What indirect holdings are noted for the CAPS CEO in this amendment?

The amendment notes that the CEO controls 121,774 additional shares through BP Peptides, LLC. These indirectly controlled shares are specifically excluded from the reported post-transaction direct holding total of 2,920,340 shares of common stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lipman Matthew E.

(Last)(First)(Middle)
18400 76TH AVENUE

(Street)
TINLEY PARK ILLINOIS 60477

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Capstone Holding Corp. [ CAPS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
04/01/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)03/30/2026A356,250(2)A(2)2,920,340(2)(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This Form 4/A is being filed solely to correct the nature of the shares reported as granted on April 1, 2026. This amendment reflects that the shares granted were shares of common stock, rather than restricted stock units.
2. Including 356,250 shares of common stock granted to the Reporting Person on March 30, 2026 as restricted stock awards, for no consideration. The restricted stock awards vest in full on March 30, 2029, which is the third anniversary of the March 30, 2026 grant date, subject to the Reporting Person's continued service through such vesting date.
3. Excludes 121,774 shares controlled by the Reporting Person, through his control of BP Peptides, LLC.
/s/ Matthew Lipman07/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)